Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma

NCT05874414 is registered in ClinicalTrials.gov with Genfit as lead sponsor.

NCT NCT05874414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05874414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1b/2a Study of GNS561 in Combination With Trametinib in Advanced KRAS Mutated Cholangiocarcinoma
Lead sponsor
Genfit
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 21, 2023
Completion date
June 30, 2028
Enrollment
98 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma